Steven T. Pals
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven T. Pals has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Marcel Spaargaren
Department of Pathology, Amsterdam University Medical Center, University of Amsterdam
15 shared publications Harmen van Andel
Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
4 shared publicationsMarie José Kersten
Lymphoma and Myeloma Center Amsterdam–LYMMCARE, The Netherlands
4 shared publicationsSander P.J. Joosten
Amsterdam University Medical Centers, University of Amsterdam, Department of Pathology, Cancer Center Amsterdam, Amsterdam, The Netherlands
4 shared publicationsHans Clevers
Hubrecht Institute, University of Utrecht, Utrecht, The Netherlands
3 shared publicationsJurrit Zeilstra
Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 30 September 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (13) , 1194-1197
Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations
- 30 September 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (13) , 1194-1197
Open AccessImmune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations
- 1 October 2019
- Published by Elsevier in Gastroenterology
- Vol. 157 (4) , 1153-1155.e1
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance
- 1 October 2019
- Published by Elsevier in Gastroenterology
- Vol. 157 (4) , 1153-1155.e1
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance
- Open Access
- 15 February 2019
- Published by Springer Nature in Leukemia
- Vol. 33 (5) , 1063-1075
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a wide variety of malignancies and is typically caused by mutations in core Wnt pathway components driving constitutive, ligand-independent signaling. In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. Recent studies indicate that this activation is caused by genetic and epigenetic lesions of Wnt regulatory components, sensitizing MM cells to autocrine Wnt ligands and paracrine Wnts emanating from the bone marrow niche. These include deletion of the tumor suppressor CYLD, promotor methylation of the Wnt antagonists WIF1, DKK1, DKK3, and sFRP1, sFRP2, sFRP4, sFRP5, as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4. Furthermore, Wnt activity in MM is strongly promoted by interaction of both Wnts and R-spondins with syndecan-1 (CD138) on the MM cell-surface. Functionally, aberrant canonical Wnt signaling plays a dual role in the pathogenesis of MM: (I) it mediates proliferation, migration, and drug resistance of MM cells; (II) MM cells secrete Wnt antagonists that contribute to the development of osteolytic lesions by impairing osteoblast differentiation. As discussed in this review, these insights into the causes and consequences of aberrant Wnt signaling in MM will help to guide the development of targeting strategies. Importantly, since Wnt signaling in MM cells is largely ligand dependent, it can be targeted by drugs/antibodies that act upstream in the pathway, interfering with Wnt secretion, sequestering Wnts, or blocking Wnt (co)receptors.
- 15 February 2019
- Published by Springer Nature in Leukemia
- Vol. 33 (5) , 1063-1075
Open AccessAberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a wide variety of malignancies and is typically caused by mutations in core Wnt pathway components driving constitutive, ligand-independent signaling. In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. Recent studies indicate that this activation is caused by genetic and epigenetic lesions of Wnt regulatory components, sensitizing MM cells to autocrine Wnt ligands and paracrine Wnts emanating from the bone marrow niche. These include deletion of the tumor suppressor CYLD, promotor methylation of the Wnt antagonists WIF1, DKK1, DKK3, and sFRP1, sFRP2, sFRP4, sFRP5, as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4. Furthermore, Wnt activity in MM is strongly promoted by interaction of both Wnts and R-spondins with syndecan-1 (CD138) on the MM cell-surface. Functionally, aberrant canonical Wnt signaling plays a dual role in the pathogenesis of MM: (I) it mediates proliferation, migration, and drug resistance of MM cells; (II) MM cells secrete Wnt antagonists that contribute to the development of osteolytic lesions by impairing osteoblast differentiation. As discussed in this review, these insights into the causes and consequences of aberrant Wnt signaling in MM will help to guide the development of targeting strategies. Importantly, since Wnt signaling in MM cells is largely ligand dependent, it can be targeted by drugs/antibodies that act upstream in the pathway, interfering with Wnt secretion, sequestering Wnts, or blocking Wnt (co)receptors.
- 1 October 2017
- Published by Elsevier in Gastroenterology
- Vol. 153 (4) , 1040-1053.e4
MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms
- 1 October 2017
- Published by Elsevier in Gastroenterology
- Vol. 153 (4) , 1040-1053.e4
MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms
- 27 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (2) , 376-381
Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins
Significance: Multiple myeloma (MM) cells are highly dependent on signals provided by the bone marrow (BM) niche for growth and survival. Most MMs display hallmarks of active Wnt signaling, but lack activating Wnt-pathway mutations, suggesting activation by autocrine Wnt ligands and/or paracrine Wnts emanating from the BM niche. In this study we uncover a pivotal role for the leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4)/R-spondin axis in facilitating activation of Wnt signaling in MM. LGR4 is expressed by most MMs, but not by healthy plasma cells, and is regulated by STAT3 signaling. LGR4 expression allows MMs to respond to (pre)osteoblast–derived R-spondins, resulting in stabilization of Wnt receptors and greatly enhanced sensitivity to auto- and paracrine Wnt ligands. These results advocate targeting of proximal Wnt signaling in MM.
- 27 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (2) , 376-381
Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins
Significance: Multiple myeloma (MM) cells are highly dependent on signals provided by the bone marrow (BM) niche for growth and survival. Most MMs display hallmarks of active Wnt signaling, but lack activating Wnt-pathway mutations, suggesting activation by autocrine Wnt ligands and/or paracrine Wnts emanating from the BM niche. In this study we uncover a pivotal role for the leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4)/R-spondin axis in facilitating activation of Wnt signaling in MM. LGR4 is expressed by most MMs, but not by healthy plasma cells, and is regulated by STAT3 signaling. LGR4 expression allows MMs to respond to (pre)osteoblast–derived R-spondins, resulting in stabilization of Wnt receptors and greatly enhanced sensitivity to auto- and paracrine Wnt ligands. These results advocate targeting of proximal Wnt signaling in MM.
- 1 June 2016
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 29 (2) , 161-168
Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia
- 1 June 2016
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 29 (2) , 161-168
Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia
- Open Access
- 20 November 2013
- Published by Springer Nature in Leukemia
- Vol. 28 (3) , 719-720
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma
- 20 November 2013
- Published by Springer Nature in Leukemia
- Vol. 28 (3) , 719-720
Open AccessHigh prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma
- Open Access
- 6 September 2013
- Published by Springer Nature in Blood Cancer Journal
- Vol. 3 (9) , e139
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
Activating mutations in CD79 and MYD88 have recently been found in a subset of diffuse large B-cell lymphoma (DLBCL), identifying B-cell receptor and MYD88 signalling as potential therapeutic targets for personalized treatment. Here, we report the prevalence of CD79B and MYD88 mutations and their relation to established clinical, phenotypic and molecular parameters in a large panel of DLBCLs. We show that these mutations often coexist and demonstrate that their presence is almost mutually exclusive with translocations of BCL2, BCL6 and cMYC, or Epstein–Bar virus infection. Intriguingly, MYD88 mutations were by far most prevalent in immune-privileged site-associated DLBCL (IP-DLBCL), presenting in central nervous system (75%) or testis (71%) and relatively uncommon in nodal (17%) and gastrointestinal tract lymphomas (11%). Our results suggest that MYD88 and CD79B mutations are important drivers of IP-DLBCLs and endow lymphoma-initiating cells with tissue-specific homing properties or a growth advantage in these barrier-protected tissues.
- 6 September 2013
- Published by Springer Nature in Blood Cancer Journal
- Vol. 3 (9) , e139
Open AccessHigh prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
Activating mutations in CD79 and MYD88 have recently been found in a subset of diffuse large B-cell lymphoma (DLBCL), identifying B-cell receptor and MYD88 signalling as potential therapeutic targets for personalized treatment. Here, we report the prevalence of CD79B and MYD88 mutations and their relation to established clinical, phenotypic and molecular parameters in a large panel of DLBCLs. We show that these mutations often coexist and demonstrate that their presence is almost mutually exclusive with translocations of BCL2, BCL6 and cMYC, or Epstein–Bar virus infection. Intriguingly, MYD88 mutations were by far most prevalent in immune-privileged site-associated DLBCL (IP-DLBCL), presenting in central nervous system (75%) or testis (71%) and relatively uncommon in nodal (17%) and gastrointestinal tract lymphomas (11%). Our results suggest that MYD88 and CD79B mutations are important drivers of IP-DLBCLs and endow lymphoma-initiating cells with tissue-specific homing properties or a growth advantage in these barrier-protected tissues.
- Open Access
- 29 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e72849
CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status
CD44 marks stem cell-like cells in a number of tumour types, including colorectal cancer (CRC), while aberrant CD44 expression conveys increased tumourigenic, invasive, and metastatic potential. Previous data indicate that CD44 is a direct target of p53-mediated transcriptional repression in breast cancer. Since inactivating p53 mutations are frequent genetic events in CRC these could unleash expression of CD44. In the present study, we therefore explored the relation between p53 mutational status and CD44 expression in a cohort of 90 localized primary CRCs and studied the effect of radiation-induced p53 activation on CD44 expression. Interestingly, we observed that, in contrast to breast cancer, loss of function p53 mutations were not associated with elevated CD44 expression in colon cancer. Moreover, DNA-damage induced p53 activation did not result in repression of CD44 expression, neither in colon cancer cells nor in normal intestinal epithelial cells. Our data demonstrate that CD44 expression in normal and malignant intestinal epithelial cells is not regulated by p53, implying that regulation of this potentially important therapeutic target is tissue and cancer-type specific.
- 29 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e72849
Open AccessCD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status
CD44 marks stem cell-like cells in a number of tumour types, including colorectal cancer (CRC), while aberrant CD44 expression conveys increased tumourigenic, invasive, and metastatic potential. Previous data indicate that CD44 is a direct target of p53-mediated transcriptional repression in breast cancer. Since inactivating p53 mutations are frequent genetic events in CRC these could unleash expression of CD44. In the present study, we therefore explored the relation between p53 mutational status and CD44 expression in a cohort of 90 localized primary CRCs and studied the effect of radiation-induced p53 activation on CD44 expression. Interestingly, we observed that, in contrast to breast cancer, loss of function p53 mutations were not associated with elevated CD44 expression in colon cancer. Moreover, DNA-damage induced p53 activation did not result in repression of CD44 expression, neither in colon cancer cells nor in normal intestinal epithelial cells. Our data demonstrate that CD44 expression in normal and malignant intestinal epithelial cells is not regulated by p53, implying that regulation of this potentially important therapeutic target is tissue and cancer-type specific.
- Open Access
- 18 February 2013
- Published by Wiley in The FEBS Journal
- Vol. 280 (10) , 2180-2193
Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma
Heparan sulfate proteoglycans (HSPGs) have essential functions during embryonic development and throughout postnatal life. To exert these functions, they undergo a series of processing reactions by heparan‐sulfate‐modifying enzymes (HSMEs), which endows them with highly modified heparan sulfate (HS) domains that provide specific docking sites for a large number of bioactive molecules. The development and antigen‐dependent differentiation of normal B lymphocytes, as well as the growth and progression of B‐lineage malignancies, are orchestrated by an array of growth factors, cytokines and chemokines many of which display HS binding. As discussed in this review, tightly regulated HSPG expression is a requirement for normal B cell maturation, differentiation and function. In addition, the HSPG syndecan‐1 functions as a versatile co‐receptor for signals from the bone marrow microenvironment, essential for the survival of long‐lived plasma cells and multiple myeloma (MM) plasma cells. Targeting of HSMEs or HS chains on MM cells increases their sensitivity to drugs currently used in MM treatment, including bortezomib, lenalidomide or dexamethasone. Taken together, these findings render the HS biosynthetic machinery a promising target for MM treatment.
- 18 February 2013
- Published by Wiley in The FEBS Journal
- Vol. 280 (10) , 2180-2193
Open AccessHeparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma
Heparan sulfate proteoglycans (HSPGs) have essential functions during embryonic development and throughout postnatal life. To exert these functions, they undergo a series of processing reactions by heparan‐sulfate‐modifying enzymes (HSMEs), which endows them with highly modified heparan sulfate (HS) domains that provide specific docking sites for a large number of bioactive molecules. The development and antigen‐dependent differentiation of normal B lymphocytes, as well as the growth and progression of B‐lineage malignancies, are orchestrated by an array of growth factors, cytokines and chemokines many of which display HS binding. As discussed in this review, tightly regulated HSPG expression is a requirement for normal B cell maturation, differentiation and function. In addition, the HSPG syndecan‐1 functions as a versatile co‐receptor for signals from the bone marrow microenvironment, essential for the survival of long‐lived plasma cells and multiple myeloma (MM) plasma cells. Targeting of HSMEs or HS chains on MM cells increases their sensitivity to drugs currently used in MM treatment, including bortezomib, lenalidomide or dexamethasone. Taken together, these findings render the HS biosynthetic machinery a promising target for MM treatment.